Trial · NCT05509374
Phase II Study of Carfilzomib, Pomalidomide, and Dexamethasone for Myeloma Patients Who Had Relapsed or Progressed After Carfilzomib, Lenalidomide, and Dexamethasone
NCT05509374, Phase 2, Unknown, Samsung Medical Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Phase II Study of Carfilzomib, Pomalidomide, and Dexamethasone for Myeloma Patients Who Had Relapsed or Progressed After Carfilzomib, Lenalidomide, and Dexamethasone. Trials, record NCT05509374. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05509374
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Phase II Study of Carfilzomib, Pomalidomide, and Dexamethasone for Myeloma Patients Who Had Relapsed or Progressed After Carfilzomib, Lenalidomide, and Dexamethasone
- NCT number
- NCT05509374
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 33 participants, estimated
- Lead sponsor
- Samsung Medical Center
- Conditions
- Multiple Myeloma
- Interventions
- Carfilzomib 56 MG [Kyprolis], Pomalidomide, Dexamethasone
- First posted
- 2022-08-22
- Last updated
- 2022-08-22
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall response rate | assessed for approximately 3 years after administration | percentage of patients who achieve at least partial response |
| Secondary | Complete response rate | assessed for approximately 3 years after administration | percentage of patients who achieve complete response |
| Secondary | Progression free survival rate | assessed for approximately 3 years after administration | percentage of patients who are disease free or alive |
| Secondary | Overall survival | assessed for approximately 3 years after administration | from the time of written consent to the time of death or last follow-up |
| Secondary | Duration of response | assessed for approximately 3 years after administration | from the time of achieving at least partial response to the time of progressive disease |
| Secondary | Time to response | assessed for approximately 3 years after administration | from the time of written consent to the time of achieving at least partial response |
| Secondary | Incidence of treatment-emergent adverse events | assessed for approximately 3 years after administration | Safety profiles of carfilzomib, pomalidomide, and dexamethasone for myeloma patients who had relapsed or progressed |
| Secondary | Minimal residual disease negativity | up to 3 years | The specimen is bone marrow aspirate, and it should be free of clonal plasma cells by examination by the NGF (next-generation flow) method. At this time, the test should be performed according to the EuroFlow standard operation procedure for MRD detection in MM, and the minimum sensitivity should be10 to the 5th power or higher. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05509374
GET https://conductscience.org/api/trials/v1/NCT05509374/registered